Partnership Opportunities

According to a recent study by Beacon Targeted Therapies, one third of all disclosed preclinical or clinical gene therapy programs are in neurology, which encompasses more prevalent diseases like Parkinson's as well as rarer conditions like ALS and Huntington's. Attendees at the 3rd Gene Therapy for Neurological Disorders meeting are seeking:

  • Neurological biomarker technology
  • Preclinical models of neurological disorders including Parkinson’s, Alzheimer’s, epilepsy and neuropathic pain
  • Preclinical CRO services with CNS expertise
  • Clinical CRO services with gene therapy expertise

Audience Breakdown

Audience Breakdown

Who's Attending in 2021?

Gene Therapy for Neurological Disorders 2021 Attendees

Partner With Us

Nathan Wilgoss

 

Nathan Wilgoss
Senior Partnerships Director
E: sponsor@hansonwade.com
T:  (+1) 617 455 4188

Adam HG

 

Adam Haras-Gummer
Senior Partnerships Director
E: sponsor@hansonwade.com
T:  (+1) 617 455 4188